Information & Referral

If you have come to our site seeking information, guidance, or referral services for yourself or another person, you have come to the right place. Wellspring is here to provide education and support to those who need assistance confronting the disease of alcoholism and drug dependence.

Information & Referral

addiction-treatment
Treatment Referrals
Suffering from an addiction problem? We can help you find a treatment facility. You can either browse through our local Treatment Directory, allow us to make suggested referrals by using our self-administered Screening Tool, or if you prefer speaking with one of our professionals, call our confidential Referral Helpline. We are available Monday through Friday from 8 a.m. to 9 p.m. You can also contact us via email at mail@wellspringprevention.org. While not intended to diagnose a substance abuse problem, each of these options will help narrow your search for a program that best meets your needs. Note that the options provided do not represent an exhaustive list of all available programs or constitute an endorsement of particular programs. However, these are programs we have worked with and have consistently received positive feedback from those who have accessed their services. If you live outside of Middlesex County New Jersey, you can get help now by calling the New Jersey Addiction Services Hotline anytime at 844-276-2777. You can also access the New Jersey Mental Health Cares Information and Referral Helpline at 1-866-202-HELP (4357).
If you live outside of New Jersey, reach out to the National Council on Alcoholism and Drug Dependence at www.ncadd.org or 212-269-7797 to find your nearest local resources.
jason-surks-memorial
Jason Surks Memorial Resource Center
The Jason Surks Memorial Prevention Resource Center at Wellspring serves as a clearinghouse for free information about alcohol, tobacco and other drugs. Explore our vast collection of online information and helpful links, or visit us at our East Brunswick, NJ location to access free pamphlets, posters and DVD lending library.
More than just a physical and web-based library, our Resource Center is people. If you need assistance planning an educational program, need information for a health fair, or would like to contract with our staff to provide presentations in your community, please call us at 732-254-3344 or send us an email request at info@wellspringprevention.org.

FDA Panel Recommends Approval of Buprenorphine Implant to Treat Addiction

image

An advisory panel to the Food and Drug Administration (FDA) recommended recently that the agency approve the buprenorphine implant Probuphine as a treatment for opioid addiction.

The FDA is not required to follow their advisory panels’ advice, but usually does so.

Probuphine provides a steady dose of buprenorphine, which eases withdrawal symptoms, decreases cravings and reduces the risk of relapse, according to USA Today.

Buprenorphine is currently sold as a pill or dissolvable film placed under the tongue.

Patients can get buprenorphine at a doctor’s office. Physicians who prescribe the drug must be certified to dispense it. They are only permitted to treat 100 patients at the time, the article notes. Buprenorphine is generally considered to be safer than methadone, because it is less likely to cause an overdose, the newspaper reports. About one million people took buprenorphine in 2012, according to the FDA.

Probuphine consists of four rods the size of a matchstick that are implanted under the skin of the upper arm, in a procedure that takes about 10 to 15 minutes in a doctor’s office. It remains in place for about six months.

The FDA is considering approving the drug for stable patients who are already using dissolvable buprenorphine film at a low dose. The panel voted 12-5 in favor of Probuphine.

Tracy Rupp, Director of Public Health Policy Initiatives at the National Center for Health Research, urged the committee to reject Probuphine. She said Braeburn Pharmaceuticals, which makes the drug, presented only one clinical study that showed the drug’s effectiveness. Rupp said the study had multiple flaws.

The FDA panel’s Acting Chairwoman, Judith Kramer, said she voted against recommending Probuphine’s approval because it is not yet known whether the drug is effective for more than six months. Many people addicted to opioids require years of treatment, she said.

Log in

fb iconLog in with Facebook
create an account